Copper peptide (GHK-Cu) in animal and human studies
The doses of copper peptide used in research vary widely depending on the research model and method of administration. Animal studies typically use a range of micrograms to milligrams per kilogram of body weight, while human studies are dominated by topical applications or low systemic exposure rather than precisely defined internal doses. In animal studies, copper peptide has been administered by intraperitoneal injection, topical application or with biomaterials, among other means. Reported experimental doses most often range from about 0.5 mg/kg to 10 mg/kg in multiple administration regimens. Some mechanistic studies also estimate a total daily exposure of 100-200 mg on a whole body basis (Pickart et al., 2014). In topical animal studies, copper peptide is typically used at low concentrations in formulations that act locally rather than systemically. This approach is common in wound and burn models, where the peptide is delivered via systems such as liposomes, hydrogels or scaffolds to promote tissue regeneration (Wang et al., 2017; Zhou et al., 2021).
In human studies, dosing is less standardized and most often pertains to topical or cosmetic applications. In clinical trials for wound healing, such as diabetic ulcers, copper peptide was applied directly to the affected areas rather than administered systemically. For this reason, it is difficult to directly compare doses between studies (Mulder et al., 1994). In newer delivery methods, such as microneedling or intradermal systems, copper peptide has been shown to be cleared relatively quickly from the body, meaning repeated applications or controlled-release systems are necessary to maintain efficacy (Li et al., 2015). Nasal and injectable administration have been mainly studied in preclinical models, particularly neurological ones; however, there are no standardized dosing regimens for humans using these methods.
From a mechanistic standpoint, dose variability arises from how copper peptide functions in the body. It is rapidly metabolized, strongly binds copper, and primarily acts locally in tissues rather than requiring high blood concentrations. Consequently, efficacy is often achieved at the site of application rather than through high systemic doses. Copper peptide used in research is available through suppliers like SemaxPolska. It is important to emphasize that doses used in animal studies and experiments do not serve as guidelines for safety or efficacy in humans, as standardized clinical dosing has not yet been established.
What concentrations of copper peptide were used in cosmetic research?
In cosmetic and dermatological research, copper peptide is typically used in low concentrations in topical preparations. Most often, these range from approximately 0.01%to 0.1%, although concentrations closer to 0.4%have been used in some formulations or research designs. In controlled human studies targeting skin aging and rejuvenation, these preparations were usually applied twice daily for 8 to 12 weeks. These studies showed improvements in skin thickness, elasticity, and a reduction in the appearance of wrinkles (Pickart & Margolina, 2018; Badenhorst et al., 2016). In controlled studies, the use of copper peptide led to measurable improvements in skin quality without significant systemic absorption, confirming its local action.
Previous studies have also shown that even low concentrations of copper peptides can stimulate skin remodeling. This is because copper peptide acts as a signaling molecule, initiating biological processes rather than exhibiting a simple dose-effect relationship typical of many substances (Reddy et al., 2012). Skin penetration studies show that copper peptide can pass through the stratum corneum and reach deeper layers, where it influences repair processes even at low concentrations (Hostynek et al., 2010).
From a mechanistic perspective, lower concentrations are effective because the copper peptide regulates gene activity, supports collagen production, and influences antioxidant pathways, rather than requiring high systemic exposure. However, it is important to note that differences in formulations, delivery systems, and study designs can affect outcomes, making direct comparisons difficult. The copper peptide used in research and formulations is available through suppliers like SemaxPolska. Concentrations used in cosmetic research should not be considered equivalent to medical dosages, and the results presented do not constitute confirmed therapeutic effects.
References
- Pickart, L., Vasquez-Soltero, J. M., & Margolina, A. (2014). GHK and DNA: Resetting the human genome to health. BioMed Research International, 2014, 151479.
- Wang, X., Liu, B., Xu, Q., Sun, H., Shi, M., & Zhang, L. (2017). GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis. Wound Repair and Regeneration, 25(2), 280–287.
- Zhou, M., Wu, X., Luo, J., Yang, G., Lu, Y., Lin, S., & Li, Y. (2021). Copper peptide-incorporated 3D-printed silk-based scaffolds promote vascularized bone regeneration. Chemical Engineering Journal, 417, 129327.
- Mulder, G. D., Patt, L. M., Sanders, L., Rosenstock, J., Altman, M. I., Hanley, M. E., & Duncan, G. W. (1994). Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration, 2(4), 259–269.
- Li, H., Low, Y. S. J., Chong, H. P., Zin, M. T., Lee, C. Y., & Li, B. (2015). Microneedle-mediated delivery of copper peptide through skin: Challenges and strategies for dermal delivery. Journal of Pharmaceutical Investigation, 45(6), 633–642.
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide in the light of new gene data. International Journal of Molecular Sciences, 19(7), 1987.
- Badenhorst, T., Svirskis, D., Merrilees, M., & Bolke, L. (2016). Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. Journal of Aging Science, 4(2), 1–8.
- Reddy, B. Y., Jow, T., & Hantash, B. M. (2012). Bioactive oligopeptides in dermatology: Part I. Experimental Dermatology, 21(8), 563–568.
- Hostynek, J. J., Dreher, F., & Maibach, H. I. (2010). Human skin retention and penetration of a copper tripeptide in vitro as a function of skin layer. Inflammation Research, 59(12), 1051–1059.